- Home
- GDTC vs RDI Comparison
GDTC vs RDI Comparison
Compare GDTC & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- RDI
- Stock Information
- Founded
- GDTC 2018
- RDI 1937
- Country
- GDTC Singapore
- RDI United States
- Employees
- GDTC N/A
- RDI N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- GDTC Health Care
- RDI Consumer Discretionary
- Exchange
- GDTC Nasdaq
- RDI Nasdaq
- Market Cap
- GDTC 33.4M
- RDI 32.3M
- IPO Year
- GDTC 2023
- RDI N/A
- Fundamental
- Price
- GDTC $2.38
- RDI $1.47
- Analyst Decision
- GDTC Buy
- RDI Hold
- Analyst Count
- GDTC 1
- RDI 1
- Target Price
- GDTC $5.00
- RDI $2.40
- AVG Volume (30 Days)
- GDTC 597.0K
- RDI 159.0K
- Earning Date
- GDTC 01-01-0001
- RDI 11-14-2024
- Dividend Yield
- GDTC N/A
- RDI N/A
- EPS Growth
- GDTC N/A
- RDI N/A
- EPS
- GDTC N/A
- RDI N/A
- Revenue
- GDTC $330,254.00
- RDI $197,270,000.00
- Revenue This Year
- GDTC $14.71
- RDI N/A
- Revenue Next Year
- GDTC N/A
- RDI $14.40
- P/E Ratio
- GDTC N/A
- RDI N/A
- Revenue Growth
- GDTC N/A
- RDI N/A
- 52 Week Low
- GDTC $1.20
- RDI $1.22
- 52 Week High
- GDTC $4.30
- RDI $2.07
- Technical
- Relative Strength Index (RSI)
- GDTC 44.91
- RDI 56.23
- Support Level
- GDTC $2.12
- RDI $1.36
- Resistance Level
- GDTC $2.64
- RDI $1.50
- Average True Range (ATR)
- GDTC 0.48
- RDI 0.09
- MACD
- GDTC -0.10
- RDI 0.01
- Stochastic Oscillator
- GDTC 13.47
- RDI 85.71
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.